Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases — NCD 158 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 158 governing IVIg coverage for autoimmune mucocutaneous blistering diseases, with an effective date of March 7, 2026. Here's what billing teams need to know.

CMS IVIg coverage policy under NCD 158 Medicare hasn't changed its core clinical criteria since October 2002 — but this 2026 modification is a formal policy update that your billing team needs to review and document. The policy covers intravenous immune globulin (IVIg) for five specific biopsy-proven blistering diseases, with strict patient eligibility requirements and a hard stop against maintenance therapy. This policy does not list specific CPT or HCPCS codes, which means your Medicare Administrative Contractor carries significant discretion here — and that creates real claim denial risk if your documentation doesn't align with your MAC's local interpretation.

Quick-Reference Table

CMS IVIg Coverage Criteria and Medical Necessity Requirements 2026

NCD 158 covers IVIg for five specific autoimmune mucocutaneous blistering diseases. Every one of them requires biopsy confirmation. There's no room for clinical suspicion or presumptive diagnosis here — if the biopsy isn't documented, the claim doesn't qualify.

The five covered conditions are:

Beyond diagnosis, medical necessity under NCD 158 rests on patient eligibility. A patient must fall into at least one of three subpopulations to qualify for coverage.

Subpopulation 1: Failed Conventional Therapy
The patient tried conventional therapy and it didn't work. Your MAC defines what "failure" means. This is not a CMS-level standard — it varies by contractor.

Subpopulation 2: Conventional Therapy Contraindicated
The patient can't safely receive conventional treatment. Again, the MAC defines contraindication. Your MAC's local coverage determination (LCD) or contractor guidance is the controlling document here, not the NCD alone.

Subpopulation 3: Rapidly Progressive Disease
The patient's disease is moving fast enough that conventional agents can't produce a clinical response quickly enough. In this case, IVIg is used alongside conventional treatment — not instead of it. IVIg stops when conventional therapy takes effect.

The third subpopulation is the most tightly defined. IVIg isn't a standalone treatment here. It's a bridge. Document that distinction clearly in the medical record, or your claim will look like unjustified maintenance therapy.

This coverage policy also carries a firm short-term therapy requirement. CMS does not cover IVIg as a maintenance therapy for these conditions. If your practice has patients receiving ongoing IVIg infusions, confirm that each treatment episode is documented as short-term and tied to an active, covered subpopulation. Your MAC decides what "short-term" means — contact them directly if you don't have that definition in writing.

CMS IVIg Exclusions and Non-Covered Indications

The NCD is narrow on purpose. Coverage applies only to the five biopsy-proven conditions listed above. IVIg for any other autoimmune skin condition — even closely related ones — falls outside NCD 158 coverage.

Maintenance therapy is explicitly excluded. If a patient has stabilized on IVIg and the treating physician wants to continue it long-term, that's not covered under this NCD. The documentation must show that the use is short-term and transitional, not ongoing disease management.

Any use of IVIg where the patient hasn't failed conventional therapy, doesn't have a documented contraindication, and isn't in a rapidly progressive disease phase falls outside the covered subpopulations. Claims billed without clear documentation of one of those three eligibility criteria will face denial.

Coverage Indications at a Glance

CMS IVIg Billing Guidelines and Action Items 2026

The absence of specific CPT or HCPCS codes in this NCD is the most important operational fact about NCD 158. It means your MAC is setting the billing rules at the local level. Here's what to do before March 7, 2026.

CPT, HCPCS, and ICD-10 Codes for IVIg Under NCD 158

A Note on Code Availability

NCD 158 does not list specific CPT, HCPCS, or ICD-10 codes. This is an important billing detail. The policy establishes coverage criteria at the national level, but code-level guidance lives at the MAC level.

Your MAC's LCD and claims processing transmittals — specifically CMS Transmittal AB-02-093 and AB-02-060, referenced in the NCD — contain the operative billing instructions. Go to those documents and your MAC's current guidance for the specific codes that apply to IVIg administration billing in your region.

What to Look For at the MAC Level

When you pull your MAC's IVIg guidance, you're looking for:

• HCPCS J-codes for the specific IVIg product being administered (products differ; codes differ)
• CPT administration codes for infusion services
• ICD-10-CM diagnosis codes for each of the five covered conditions — Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita

Do not use codes from a prior MAC policy or a different payer's IVIg guidance without confirming they're current. HCPCS J-codes for biologics change. Verify.